LOY-002
LOY-002, canine lifespan-extension drug (Loyal)
A daily pill for senior dogs that could become the first drug the FDA has ever approved for extending lifespan; the agency accepted its safety and effectiveness packages in 2025 and 2026.
Overview
LOY-002 is Loyal's oral small molecule addressing age-related metabolic dysfunction in dogs aged ten and older. The FDA's Center for Veterinary Medicine accepted the reasonable-expectation-of-effectiveness section in February 2025 and the target-animal-safety section in January 2026, both firsts for a longevity drug. The STAY pivotal trial enrolled 1,300 dogs across 70 clinics. Conditional approval could come in late 2026 or 2027. The exact target has not been disclosed.
Mechanism of action
Undisclosed; described as correcting age-associated metabolic dysfunction.
Key studies & citations
- Animal2026
Loyal receives FDA acceptance of safety package for senior dog lifespan extension drug
First safety acceptance for any lifespan drug.
Loyal press release - Animal2025
Loyal receives FDA acceptance of reasonable expectation of effectiveness
Regulator agreed the drug could plausibly extend lifespan.
Loyal press release
Frequently asked questions
Why is a dog drug on a human longevity site?
Because regulatory acceptance that lifespan can be a drug endpoint is a milestone for the whole field, and the human parallels (metabolic aging) are the same ones behind GLP-1 and mTOR research.